AstraZeneca has partnered with California biotech startup insitro in a deal valued at up to $1.5 billion to discover treatments for difficult-to-treat heart and liver conditions. AstraZeneca will pay $40 million upfront, with insitro eligible for $1.46 billion in milestones plus royalties. Insitro will deploy its Virtual Human AI platform to identify targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, while AstraZeneca will run clinical trials.
AstraZeneca-insitro AI drug discovery partnership
- ▪Under the October 15, 2026 agreement, insitro is eligible to receive a single-digit percentage of future product sales in royalties from therapies developed through the AstraZeneca partnership
- ▪AstraZeneca secured exclusive worldwide rights to advance programs identified through its October 15, 2026 partnership with insitro and will fund and run all clinical development, regulatory work, and commercialization activities
- ▪AstraZeneca entered a multi-year partnership with insitro on October 15, 2026, paying $40 million upfront with insitro eligible for up to $1.46 billion in potential development and commercial milestones
MASH therapeutic target identification
- ▪Metabolic dysfunction-associated steatohepatitis has historically lacked effective therapies because medical researchers have struggled to pinpoint the disease's root biological drivers
- ▪The AstraZeneca and insitro collaboration focuses on identifying therapeutic targets for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease also known as fatty liver disease
Cardiomyopathy therapeutic target identification
- ▪The AstraZeneca and insitro collaboration announced on October 15, 2026 focuses on identifying therapeutic targets for cardiomyopathies, a group of diseases that affect the heart muscle
- ▪Metabolic dysfunction-associated steatohepatitis has historically lacked effective therapies because medical researchers have struggled to pinpoint the disease's root biological drivers
AI-driven pharmaceutical R&D strategy
- ▪AstraZeneca Executive Vice President Sharon Barr stated that pairing artificial intelligence tools with experienced scientists allows AstraZeneca to test fewer molecules in the lab, reduce guesswork, and accelerate drug discovery
- ▪Pharmaceutical competitor Novo Nordisk partnered with Anthropic last month to use the Claude Science platform for drug research, while Roche partnered with Nvidia earlier in 2026 to build a supercomputer
- ▪AstraZeneca Executive Vice President Sharon Barr stated on October 15, 2026, that identifying target pathways early using cellular systems allows AstraZeneca to discover novel targets before they enter the public domain
Insitro Bristol Myers Squibb collaboration
- ▪Insitro partnered with Eli Lilly to build artificial intelligence models that predict the pharmacological properties of small molecules in living organisms
- ▪Insitro previously expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of therapeutic targets for amyotrophic lateral sclerosis (ALS)
Story comments
Loading comments…